PMID- 35999610
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220827
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 14
IP  - 1
DP  - 2022 Aug 23
TI  - New insights into the role of empagliflozin on diabetic renal tubular lipid 
      accumulation.
PG  - 121
LID - 10.1186/s13098-022-00886-x [doi]
LID - 121
AB  - BACKGROUND: Glucose cotransporter (SGLT) 2 suppression provides potent renal 
      protective effect during diabetic kidney disease (DKD). This work aimed to 
      explore how empagliflozin (EMPA, the selective and strong inhibitor of SGLT2) 
      affected renal lipid deposition among patients undergoing type 2 diabetes 
      mellitus (T2DM), a T2DM mouse model and human renal proximal tubular epithelial 
      (HK-2) cells. METHODS: This work divided subjects as 3 groups: non-diabetic 
      volunteers, patients treated with metformin and those treated with metformin plus 
      EMPA. In an in vivo study, EMPA was adopted for treating db/db mice that were 
      raised with the basal diet or the high-advanced glycation end products (AGEs) 
      diet. In addition, AGEs and/or EMPA was utilized to treat HK-2 cells in vitro. 
      RESULTS: Results showed that diabetic patients treated with metformin plus EMPA 
      had lower AGEs levels and renal fat fraction (RFF) than those treated with 
      metformin. Moreover, a significant and positive association was found between 
      AGEs and RFF. Results from the basic study showed that EMPA decreased cholesterol 
      level, tubular lipid droplets, and protein levels related to cholesterol 
      metabolism in AGEs-mediated HK-2 cells, kidneys of db/db mice and those fed with 
      the high-AGEs diet. Additionally, EMPA decreased AGEs levels in serum while 
      inhibiting the expression of receptor of AGEs (RAGE) in vitro and in vivo. 
      CONCLUSION: EMPA inhibited the AGEs-RAGE pathway, thereby alleviating diabetic 
      renal tubular cholesterol accumulation.
CI  - (c) 2022. The Author(s).
FAU - Sun, Hong
AU  - Sun H
AD  - Department of Endocrinology and Metabolism, Dushu Lake Hospital Affiliated to 
      Soochow University, Medical Center of Soochow University, Suzhou, Jiangsu, China. 
      sunhong_611@126.com.
FAU - Chen, Juan
AU  - Chen J
AD  - Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, 
      Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Hua, Yulin
AU  - Hua Y
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Soochow University, Suzhou, Jiangsu, China.
FAU - Zhang, Yuyang
AU  - Zhang Y
AD  - The First Clinical Medical College, Soochow University, Suzhou, Jiangsu, China.
FAU - Liu, Zheng
AU  - Liu Z
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Soochow University, Suzhou, Jiangsu, China. liuzheng06@suda.edu.cn.
LA  - eng
GR  - SYS2020104/People's Livelihood Science and Technology of Suzhou/
GR  - 81700632/National Natural Science Youth Foundation of China/
GR  - 81900794/National Natural Science Youth Foundation of China/
GR  - BK20170366/Natural Science Youth Foundation of Jiangsu Province/
GR  - 2020M671559/Postdoctoral Science Foundation of Guangxi Province of China/
PT  - Journal Article
DEP - 20220823
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC9396853
OTO - NOTNLM
OT  - Advanced glycation end products
OT  - Diabetic kidney disease
OT  - Empagliflozin
OT  - Renal fat fractions
COIS- The authors declare no cmpeting interests.
EDAT- 2022/08/24 06:00
MHDA- 2022/08/24 06:01
PMCR- 2022/08/23
CRDT- 2022/08/23 23:40
PHST- 2022/04/04 00:00 [received]
PHST- 2022/08/04 00:00 [accepted]
PHST- 2022/08/23 23:40 [entrez]
PHST- 2022/08/24 06:00 [pubmed]
PHST- 2022/08/24 06:01 [medline]
PHST- 2022/08/23 00:00 [pmc-release]
AID - 10.1186/s13098-022-00886-x [pii]
AID - 886 [pii]
AID - 10.1186/s13098-022-00886-x [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2022 Aug 23;14(1):121. doi: 10.1186/s13098-022-00886-x.